FrancophonIA/ELRC3.0 huggingface dataset:
English: Gastroesophageal reflux disease
Croatian: Gastroezofagealna refluksna bolest rijetko
English: Table 5: Transporter interactions
Croatian: Tablica 5: Interakcije na razini transportnih mehanizama
English: Pradaxa 150 mg once daily
Croatian: Pradaxa 150 mg jedanput dnevno
English: Dialysis was conducted with 700 mL/min dialysate flow rate, four hour duration and a blood flow rate of either 200 mL/min or 350-390 mL/min.
Croatian: Dijaliza je provedena s brzinom protoka dijalizata od 700 mL/min, u trajanju četiri sata te sa stopom protoka krvi od ili 200 mL/min ili 350-390 mL/min.
English: INFORMATION IN BRAILLE Pradaxa 110 mg (only applicable for folding box, not applicable for bottle label)
Croatian: 16. PODACI NA BRAILLEOVOM PISMU Pradaxa 110 mg (primjenjivo samo za kutiju, nije primjenjivo za naljepnicu na boci)
English: Blood and lymphatic system disorders Haemoglobin decreased
Croatian: Poremećaji krvi i limfnog sustava Sniženi hemoglobin često
English: Pradaxa treatment should be resumed / started after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established.
Croatian: Liječenje Pradaxom treba se nastaviti/započeti nakon invazivnog postupka ili kirurške intervencije čim je prije moguće uz uvjet da to dopušta klinička situacija i da je uspostavljena odgovarajuća hemostaza.
English: • Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc), oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances.
Croatian: • Istovremeno liječenje drugim antikoagulansom, npr. nefrakcioniranim heparinom (UFH), niskomolekularnim heparinom (enoksaparin, dalteparin, itd), derivatima heparina (fondaparinuks, itd.), oralnim antikoagulansima (varfarin, rivaroksaban, apiksaban, itd.) osim u specifičnim okolnostima.
English: • the 90th percentile of aPTT at trough (10-16 hours after the previous dose) was 62 seconds, which would be 1.8-fold compared to baseline.
Croatian: • 90. percentila aPTT pri kraju dozirnog intervala (10 - 16 sati nakon prethodne doze) bila je 62 sekunde, što bi bilo 1,8 puta više u usporedbi s početnom vrijednošću.
English: While certain patient subgroups are at an increased risk of major bleeding when treated with an anticoagulant, the excess bleeding risk for dabigatran is due to GI bleeding, typically seen within the first 3-6 months following initiation of Pradaxa therapy.
Croatian: Dodatni rizik koji je posljedica primjene dabigatrana odnosi se na povećan rizik od gastrointestinalnog krvarenja koje se obično vidi unutar 3 - 6 mjeseci liječenja Pradaxom.
English: Pradaxa 110 mg are hard capsules with an opaque, light blue-coloured cap and an opaque, light blue -coloured body.
Croatian: Pradaxa 110 mg su tvrde kapsule s neprozirnom, svijetloplavom kapicom i neprozirnim tijelom svijetloplave boje.
English: Assessment of renal function prior to and during Pradaxa treatment In all patients and especially in the elderly (>75 years), as renal impairment may be frequent in this age group:
Croatian: U svih bolesnika, a osobito starijih osoba (u dobi >75 godina), jer oštećenje bubrega može biti često u toj dobnoj skupini:
English: When excessive dabigatran exposure is identified in patients at high risk of bleeding, a reduced dose of 220 mg taken as one 110 mg capsule twice daily is recommended.
Croatian: Kada se prekomjerna izloženost dabigatranu prepozna u bolesnika s visokim rizikom od krvarenja, preporučuje se snižena doza od 220 mg u obliku jedne kapsule od 110 mg dvaput dnevno.
English: 4.7 Effects on ability to drive and use machines Pradaxa has no or negligible influence on the ability to drive and use machines.
Croatian: Pradaxa ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Pradaxa 110 mg hard capsules are also available in polypropylene (plastic) bottles with 60 hard capsules.
Croatian: Pradaxa 110 mg tvrde kapsule također su dostupne u polipropilenskoj (plastičnoj) boci sa60 tvrdih kapsula.
English: - Belly ache or stomach ache - Indigestion - Difficulty in swallowing - Fluid exiting a wound - Fluid exiting a wound after an operation
Croatian: - Probavne tegobe - Otežano gutanje - Tekućina koja izlazi iz rane - Tekućina koja izlazi iz rane nakon operacije
English: Pradaxa is available in packs containing 10 x 1, 30 x 1 or 60 x 1 capsules in aluminium perforated unit dose blisters.
Croatian: Pradaxa je dostupna u pakiranjima s 10 x 1, 30 x 1 ili 60 x 1 kapsula u aluminijskim perforiranim blisterima s jediničnim dozama.
English: Half-life is prolonged if renal function is impaired as shown in table 23.
Croatian: Poluvijek se produljuje ako je bubrežna funkcija oštećena sukladno prikazanom u tablici 23.
English: • Mild to moderate P-gp inhibitor co-medication (e.g. amiodarone, verapamil, quinidine and ticagrelor; see section 4.5)
Croatian: • istodobna primjena blagih do umjerenih P-gp inhibitora (npr. amiodarona, verapamila, kinidina i tikagrelora; vidjeti dio 4.5)
English: For patients randomized to warfarin, the mean percentage of time in therapeutic range (TTR) (INR 2-3) was 64.4 % (median TTR 67 %).
Croatian: Za bolesnike randomizirane na varfarin, aritmetička sredina postotka vremena u terapijskom rasponu (TTR) (INR 2-3) iznosila je 64,4 % (medijan TTR je iznosio 67 %).
English: RE-NOVATE (hip) Treated patients N Number of MBE N(%) RE-MODEL (knee) Treated patients N Number of MBE N(%)
Croatian: RE-NOVATE (kuk) Broj liječenih bolesnika Broj događaja velikih krvarenja N(%) RE-MODEL (koljeno) Broj liječenih bolesnika Broj događaja velikih krvarenja N(%)
English: Some bleeding events (MBEs/CRBEs; any bleeding) were significantly lower at a nominal alpha level of 5% in patients receiving Pradaxa as compared with those receiving warfarin.
Croatian: Pojedini događaji krvarenja (MBE-i/CRBE-i (engl. major bleeding events/clinically relevant bleeding events); svako krvarenje) bili su značajno manji na nominalnoj alfa-razini 5% kod bolesnika na Pradaxi u usporedbi sa bolesnicima koji su primali varfarin.
English: Pradaxa 110 mg twice daily
Croatian: Pradaxa 110 mg dvaput dnevno
English: • Patient Alert Cards
Croatian: • Kartice s upozorenjima za bolesnike
English: Prevention of brain or body vessel obstruction by blood clot formation developing after abnormal heart beats
Croatian: Prevencija začepljenja krvnih žila mozga ili tijela stvaranjem krvnih ugrušaka koji se stvaraju nakon nepravilnih otkucaja srca
English: Patients following elective hip replacement surgery
Croatian: Bolesnici nakon elektivnog kirurškog zahvata ugradnje endoproteze kuka
English: PHARMACEUTICAL FORM AND CONTENTS 10 x 1 hard capsule
Croatian: OBLIK I SADRŽAJ 10 x 1 tvrda kapsula
English: • Do not stop intake of Pradaxa
Croatian: • Ne prekidajte primjenu Pradaxe
English: INFORMATION IN BRAILLE Pradaxa 150 mg (only applicable for folding box, not applicable for bottle label)
Croatian: 16. PODACI NA BRAILLEOVOM PISMU Pradaxa 150 mg (primjenjivo samo za kutiju, nije primjenjivo za naljepnicu na boci)
English: Carton containing 6 blister strips (60 x 1) in perforated aluminium unit dose white blisters.
Croatian: Kutija koja sadrži 6 blister stripova (60 x 1) u bijelim perforiranim aluminijskim blisterima s jediničnim dozama.
English: Prevention of blood clot formation after knee or hip replacement surgery
Croatian: Prevencija stvaranja krvnog ugruška nakon kirurškog zahvata ugradnje koljena ili kuka
English: They are ranked under headings of System Organ Class (SOC) and frequency using the following convention: very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare ( 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Croatian: Poredane su prema klasifikaciji organskih sustava i učestalosti, uz sljedeću konvenciju: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nije poznato (ne može se utvrditi iz dostupnih podataka).
English: Primary VTE prevention after hip or knee replacement surgery
Croatian: Primarna VTE prevencija nakon zahvata ugradnje kuka ili koljena
English: When a loading dose of 180 mg ticagrelor was given 2 hours after 110 mg dabigatran etexilate (in steady state), the increase of dabigatran AUCτ,ss and Cmax,ss was reduced to 1.27-fold and 1.23-fold, respectively, compared with dabigatran etexilate given alone.
Croatian: Kada je udarna doza od 180 mg tikagrelora primjenjivana 2 sata nakon 110 mg dabigatraneteksilata (u stanju dinamičke ravnoteže), povećanje AUCτ,ss dabigatrana bilo je smanjeno na 1,27 puta, a njegov Cmax,ss na 1,23 puta u usporedbi s monoterapijom dabigatraneteksilata.
English: In patients treated for prevention of VTEs after hip or knee replacement surgery with 220 mg dabigatran etexilate once daily,
Croatian: Kod bolesnika liječenih radi prevencije VTE-a nakon kirurškog zahvata ugradnje endoproteze kuka ili koljena s 220 mg dabigatraneteksilata jedanput dnevno,
English: - if you need to have an operation:
Croatian: Budite posebno oprezni s Pradaxom ako trebate imati operaciju:
English: - The capsule shell contains carrageenan, potassium chloride, titanium dioxide, and hypromellose.
Croatian: - Ovojnica kapsule sadrži karagenan, kalijev klorid, titanijev dioksid i hipromelozu.
English: Capsules with light blue, opaque cap and light blue, opaque body of size 1 filled with yellowish pellets.
Croatian: Kapsule sa svijetloplavom, neprozirnom kapicom i svijetloplavim, neprozirnim tijelom veličine 1, napunjene žućkastim peletima.
English: Table 10 shows the adverse reactions identified studies and post-marketing data in the indications prevention of thromboembolic stroke and systemic embolism in patients with atrial fibrillation, DVT/PE treatment and DVT/PE prevention.
Croatian: Tablica 10 prikazuje nuspojave identificirane iz podataka iz ispitivanja i razdoblja nakon stavljanja lijeka u promet za indikacije prevencije tromboemolijskog moždanog udara i sistemske embolije u bolesnika s fibrilacijom atrija, te liječenja DVT/PE-a i prevencije DVT/PE-a.
English: PATIENT ALERT CARD Table of Content
Croatian: KARTICA S UPOZORENJIMA ZA BOLESNIKA
English: Subjects randomized Stroke and/or systemic embolism Incidences (%) Hazard ratio over warfarin (95 % CI) p value superiority p=0.2721
Croatian: Moždani udar i/ili sistemska embolija Incidencije (%) HR naspram varfarina (95 % CI) p-vrijednost superiornosti p=0,2721
English: Table 24: Hazard Ratio and 95 % CI for major bleeds by subgroups Endpoint
Croatian: Tablica 24: Omjer hazarda i 95 % CI za velika krvarenja po podskupinama Ishodna točka
English: A calibrated quantitative dTT test or repetitive dTT measurements allow prediction of the time by when certain dabigatran levels will be reached (see section 5.1), also in case additional measures e.g. dialysis have been initiated.
Croatian: Kalibrirani kvantitativni dTV test ili ponovljena mjerenja dTV omogućuju predviđanje vremena do kojeg će se postići određene koncentracije dabigatrana u plazmi (vidjeti dio 5.1).
English: RE-MODEL (knee) Treated patients N Number of MBE N(%)
Croatian: RE-MODEL (koljeno) Broj liječenih bolesnika Broj velikih krvarenja N(%)
English: The clinical evidence for the efficacy of dabigatran etexilate is derived from the RE-LY study (Randomized Evaluation of Long -term anticoagulant therapy) a multi-centre, multi-national, randomized parallel group study of two blinded doses of dabigatran etexilate (110 mg and 150 mg twice daily) compared to open-label warfarin in patients with atrial fibrillation at moderate to high risk of stroke and systemic embolism.
Croatian: Klinički dokaz djelotvornosti dabigatraneteksilata potječe iz RE-LY studije (Randomizirana ocjena dugotrajne antikoagulacijske terapije - Randomized Evaluation of Long-term anticoagulant therapy) multicentričnog, multinacionalnog, randomiziranog pokusa paralelnih grupa, s dvije dvostruko slijepe doze dabigatraneteksilata (110 mg i 150 mg dvaput dnevno) u usporedbi s “otvorenim” varfarinom u bolesnika s fibrilacijom atrija i umjerenim do visokim rizikom od moždanog udara i sistemske embolije.
English: Further risk factors (see also table 4) comprise co-medication with platelet aggregation inhibitors such as clopidogrel and acetylsalicylic acid (ASA) or non steroidal antiinflammatory drugs (NSAID), as well as the presence of esophagitis, gastritis or gastroesophageal reflux.
Croatian: Dodatni faktori rizika (vidjeti također tablicu 4) uključuju istodobno liječenje inhibitorima agregacije trombocita poput klopidogrela i acetilsalicilatne kiseline (ASK) ili nesteroidnim protuupalnim lijekovima (NSAIL), kao i prisustvo ezofagitisa, gastritisa, ili gastroezofagealnog refluksa.
English: Further risk factors (see also table 3) comprise co-medication with platelet aggregation inhibitors such as clopidogrel and acetylsalicylic acid (ASA) or non steroidal antiinflammatory drugs (NSAID), as well as the presence of esophagitis, gastritis or gastroesophageal reflux.
Croatian: Dodatni faktori rizika (vidjeti također tablicu 3) uključuju istodobno liječenje inhibitorima agregacije trombocita poput klopidogrela i acetilsalicilatne kiseline (ASK) ili nesteroidnim protuupalnim lijekovima (NSAIL), kao i prisustvo ezofagitisa, gastritisa, ili gastroezofagealnog refluksa.
English: Table 19: Hazard Ratio and 95 % CI for major bleeds by subgroups Endpoint
Croatian: Tablica 19: Omjer hazarda i 95 % CI za velika krvarenja po podskupinama Ishodna točka
English: Therefore, related medicinal product interactions are not expected with dabigatran.
Croatian: Stoga se ne očekuju interakcije dabigatrana i lijekova koji se metaboliziraju tim enzimskim sustavom.
English: The clinical evidence for the efficacy of dabigatran etexilate is derived from the RE-LY study (Randomized Evaluation of Long-term anticoagulant therapy) a multi-centre, multi-national, randomized parallel group study of two blinded doses of dabigatran etexilate (110 mg and 150 mg twice daily) compared to open-label warfarin in patients with atrial fibrillation at moderate to high risk of stroke and systemic embolism.
Croatian: Klinički dokaz djelotvornosti dabigatraneteksilata potječe iz RE-LY studije (Randomizirana ocjena dugotrajne antikoagulacijske terapije - Randomized Evaluation of Long-term anticoagulant therapy) multicentričnog, multinacionalnog, randomiziranog ispitivanja na paralelnim skupinama, s dvije dvostruko slijepe doze dabigatraneteksilata (110 mg i 150 mg dvaput dnevno) u usporedbi s “otvorenim” varfarinom u bolesnika s fibrilacijom atrija i umjerenim do visokim rizikom od moždanog udara i sistemske embolije.
English: Patients aged 75 or above *For patients with moderate renal impairment concomitantly treated with verapamil see Special populations
Croatian: *Za bolesnike s umjerenim oštećenjem bubrega koji se istovremeno liječe verapamilom vidjeti Posebne populacije
English: Pradaxa 150 mg hard capsules are also available in polypropylene (plastic) bottles with 60 hard capsules.
Croatian: Pradaxa 150 mg tvrde kapsule također su dostupne u polipropilenskoj (plastičnoj) boci sa60 tvrdih kapsula.
English: - The capsule shell contains carrageenan, potassium chloride, titanium dioxide, indigo carmine, and hypromellose.
Croatian: Ovojnica kapsule sadrži karagenan, kalijev klorid, titanijev dioksid, indigo karmin i hipromelozu.
English: Pradaxa 150 mg twice daily
Croatian: Pradaxa 150 mg dvaput dnevno
English: Furthermore, Pradaxa is available in packs containing 60 x 1 capsules in aluminium perforated unit dose white blisters.
Croatian: Nadalje, Pradaxa je dostupna u pakiranjima koja sadrže 60 x 1 kapsulu u bijelim aluminijskim perforiranim blisterima s jediničnim dozama.
English: Hazard ratio vs placebo (95% confidence interval)
Croatian: Omjer hazarda naspram placeba (interval pouzdanosti 95%)
English: treat blood clots in the veins of your legs and lungs and to prevent blood clots from reoccurring in the vein of your legs and lungs.
Croatian: - liječenje krvnih ugrušaka u venama nogu i pluća te za sprječavanje ponovne pojave krvnih ugrušaka u venama nogu i pluća.
English: Tartaric acid
Croatian: Acetilsalicilatna kiselina
English: Multipack containing 3 packs of 60 x 1 hard capsules (180 hard capsules) in perforated aluminium unit dose blisters.
Croatian: Višestruko pakiranje koje sadrži 3 pakiranja sa 60 x 1 tvrdom kapsulom (180 tvrdih kapsula) u perforiranim aluminijskim blisterima s jediničnim dozama.
English: For patients randomized to warfarin, the median time in therapeutic range (INR 2.0-3.0) was 64.9 %.
Croatian: Za bolesnike randomizirane na varfarin, medijan vremena u terapijskom rasponu (INR 2,0-3,0) bio je 64,9 %.
English: PHARMACEUTICAL FORM AND CONTENTS Multipack: 180 (3 packs of 60x1) hard capsules.
Croatian: OBLIK I SADRŽAJ Višestruko pakiranje: 180 (3 pakiranja sa 60 x 1) tvrdih kapsula.
English: Subjects randomized to Pradaxa 110 mg twice daily or 150 mg twice daily had a significantly lower risk for life-threatening bleeds and intracranial bleeding compared to warfarin [p < 0.05].
Croatian: Bolesnici randomizirani na liječenje Pradaxom 110 mg dvaput dnevno ili 150 mg dvaput dnevno imali su značajno niži rizik od po život opasnih krvarenja i intrakranijalnog krvarenja u usporedbi s varfarinom [p < 0,05].
English: PHARMACEUTICAL FORM AND CONTENTS Multipack:100 (2 packs of 50x1) hard capsules.
Croatian: OBLIK I SADRŽAJ Višestruko pakiranje: 100 (2 pakiranja sa 50 x 1) tvrdih kapsula.
English: If you are taking verapamil containing medicines, your doctor will tell you to use a reduced dose of Pradaxa.
Croatian: Ako uzimate lijekove koji sadrže verapamil, liječnik Vam može savjetovati da uzimate sniženu dozu Pradaxe.
English: Table 10: Adverse reactions
Croatian: Tablica 10: Nuspojave
English: In a dedicated study exclusively in patients with moderate renal impairment (creatinine clearance, CrCL 30-50 mL/min) treated with dabigatran etexilate 150 mg QD, the dabigatran geometric mean trough concentration, measured at the end of the dosing interval, was on average 47.5 ng/mL, with a range of 29.6 - 72.2 ng/mL (25
Croatian: U ispitivanju provedenom isključivo na bolesnicima s umjerenim oštećenjem bubrega (klirens kreatinina, CrCl 30 - 50 mL/min) liječenim dabigatraneteksilatom 150 mg jedanput dnevno , geometrijska srednja najniža vrijednost koncentracije dabigatrana mjerena na kraju dozirnog intervala bila je u prosjeku 47,5 ng/mL, s rasponom 29,6 - 72,2 ng/mL (percentilni raspon 25.-75.).
English: Subjects randomized All-cause mortality Incidences (%) Hazard ratio vs. warfarin (95 % CI) p-value Vascular mortality Incidences (%) Hazard ratio vs. warfarin (95 % CI) p-value % refers to yearly event rate
Croatian: Randomizirani ispitanici Smrtnost svih uzroka Incidencije (%) HR naspram varfarina (95 % CI) p-vrijednost Vaskularna smrtnost Incidencija (%) HR naspram varfarina (95 % CI) p-vrijednost % se odnosi na godišnju stopu događaja
English: Use of fibrinolytic medicinal products for the treatment of acute ischemic stroke The use of fibrinolytic medicinal products for the treatment of acute ischemic stroke may be considered if the patient presents with a dTT, ECT or aPTT not exceeding the upper limit of normal (ULN) according to the local reference range.
Croatian: Primjena fibrinolitika u liječenju akutnog ishemijskog moždanog udara Primjena fibrinolitika u liječenju akutnog ishemijskog moždanog udara može se razmotriti u slučaju kada se bolesnik prijavi s dTV, ECT ili aPTV koje ne prelaze gornju granicu normale (GGN) prema referentnom lokalnom rasponu.
English: Prevention of stroke and systemic embolism in adult patients with NVAF with one or more risk factors
Croatian: Prevencija moždanog udara i sistemske embolije u odraslih bolesnika s NVAF-om s jednim ili više rizičnih faktora
English: Intracranial bleeding GI bleeding Fatal bleeding Minor bleeding Any bleeding
Croatian: Manje krvarenje Bilo kakvo krvarenje
English: Half-life is prolonged if renal function is impaired as shown in table 28.
Croatian: Poluvijek se produljuje ako je bubrežna funkcija oštećena sukladno prikazanom u tablici 28.
English: Pradaxa 150 mg hard capsules dabigatran etexilate
Croatian: Pradaxa 150 mg tvrde kapsule dabigatraneteksilat
English: Table 7: Interactions with anticoagulants and antiplatelet aggregation medicinal products NSAIDs
Croatian: Tablica 7: Interakcije s antikoagulansima i inhibitorima agregacije trombocita NSAIL-i
English: Half-life is prolonged if renal function is impaired as shown in table 13.
Croatian: Poluvijek se produljuje ako je bubrežna funkcija oštećena sukladno prikazanom u tablici 13.
English: Capsules with light blue, opaque cap and white, opaque body of size 0 filled with yellowish pellets.
Croatian: Kapsule sa svijetloplavom, neprozirnom kapicom i bijelim, neprozirnim tijelom veličine 0, napunjene žućkastim peletima.
English: Primary prevention of venous thromboembolism in orthopaedic surgery
Croatian: Primarna prevencija venske tromboembolije u ortopedskoj kirurgiji
English: Table 23: Hazard Ratio and 95 % CI for stroke/systemic embolism by subgroups
Croatian: Tablica 23: Relativni rizik i 95 % CI za moždani udar/sistemsku emboliju po podskupinama
English: Post procedural drainage
Croatian: Postproceduralna drenaža AQ
English: Concomitant administration of a loading dose of 180 mg ticagrelor and 110 mg dabigatran etexilate (in steady state) increased the dabigatran AUCτ,ss and Cmax,ss by 1.49-fold and 1.65-fold, respectively, compared with dabigatran etexilate given alone.
Croatian: Istodobna primjena udarne doze od 180 mg tikagrelora i 110 mg dabigatraneteksilata (u stanju dinamičke ravnoteže) povećala je AUCτ,ss dabigatrana za 1,49 puta, a njegov Cmax,ss za 1,65 puta u usporedbi s monoterapijom dabigatraneteksilata.
English: NAME OF THE MEDICINAL PRODUCT Pradaxa 75 mg hard capsules
Croatian: NAZIV LIJEKA Pradaxa 75 mg tvrde kapsule
English: Skin and subcutaneous tissue disorder Skin haemorrhage
Croatian: Poremećaji kože i potkožnog tkiva Krvarenje kože često često
English: In patients treated for DVT and PE with 150 mg dabigatran etexilate twice daily, the dabigatran geometric mean trough concentration, measured within 10−16 hours after dose, at the end of the dosing interval (i.e. 12 hours after the 150 mg dabigatran evening dose), was 59.7 ng/ml, with a range of 38.6 - 94.5 ng/ml (25th-75th percentile range).
Croatian: Kod bolesnika koji se liječe zbog DVT i PE s 150 mg dabigatraneteksilata dvaput dnevno, geometrijski prosjek minimalne koncentracije dabigatrana, mjerene unutar 10 − 16 sati nakon primjene doze, pri kraju dozirnog intervala (tj. 12 sati nakon večernje doze 150 mg dabigatrana), bio je 59,7 ng/ml, s rasponom od 38,6 - 94,5 ng/ml (raspon 25.-75. percentile).
English: Hazard ratio vs warfarin (95% confidence interval) non-inferiority margin Patients with event at 18 months Cumulative risk at
Croatian: Rekurentni simptomatski VTE i smrt povezana s VTE-om Omjer hazarda naspram varfarina (interval pouzdanosti 95%) Granica neinferiornosti Bolesnici s događajem nakon 18 mjeseci
English: INFORMATION IN BRAILLE Pradaxa 150 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU Pradaxa 150 mg
English: Anticoagulants and antiplatelet aggregation medicinal products
Croatian: Antikoagulansi i inhibitori agregacije trombocita
English: 300 mg Pradaxa taken as one 150 mg capsule twice daily
Croatian: 300 mg Pradaxe uzeta u obliku jedne kapsule od 150 mg dvaput dnevno
English: Pradaxa 110 mg hard capsules dabigatran etexilate
Croatian: Pradaxa 110 mg tvrde kapsule dabigatraneteksilat
English: • an ECT at trough (10-16 hours after the previous dose), elevated approximately 2.3-fold compared to baseline refers to the observed 90th percentile of ECT prolongation of 74 seconds,
Croatian: • ECT pri kraju dozirnog intervala (10-16 sati nakon prethodne doze) povišen za oko 2,3 puta u usporedbi s početnom vrijednošću odnosi se na opservaciju 90. percentile ECT produljenja od 74 sekundi,
English: Blood and lymphatic system disorders Anaemia
Croatian: Poremećaji krvi i limfnog sustava Anemija često manje često